<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465996</url>
  </required_header>
  <id_info>
    <org_study_id>2015SDU-QILU-G02</org_study_id>
    <nct_id>NCT02465996</nct_id>
  </id_info>
  <brief_title>Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy</brief_title>
  <official_title>Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional dyspepsia might have impaired gastric mucosal dysfunction and Puyuanhewei may be
      helpful to improve the symptoms of FD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aimed to investigate the gastric mucosal dysfunction in functional dyspepsia (FD)
      and verify the efficacy of Puyuanhewei for treating FD and assess the relationship between
      gastric microalterations and therapeutic response by endomicroscopy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCLE score</measure>
    <time_frame>within 1 hour after pCLE examination</time_frame>
    <description>Used to assess the gastric barrier dysfunction of FD patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leeds dyspepsia questionaire</measure>
    <time_frame>baseline and 4th week</time_frame>
    <description>Used to describe the change of severity of FD from baseline to the 4th week during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main dyspepsia symptom score</measure>
    <time_frame>baseline and 4th weeks</time_frame>
    <description>Used to describe the change of severity and frequency of despepsia symptoms from baseline to the 4th week during the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>postprandial distress syndrome (PDS)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FD patients fulfilled Rome III criteria were subclassified into postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS).
pCLE examination was performed in PDS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epigastric pain syndrome (EPS)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>pCLE examination was performed in EPS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pCLE examination</intervention_name>
    <description>All FD patients received pCLE examination.</description>
    <arm_group_label>postprandial distress syndrome (PDS)</arm_group_label>
    <arm_group_label>epigastric pain syndrome (EPS)</arm_group_label>
    <other_name>prob-based confocal laser endomicroscopy examination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Puyuanhewei</intervention_name>
    <description>FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.</description>
    <arm_group_label>postprandial distress syndrome (PDS)</arm_group_label>
    <arm_group_label>epigastric pain syndrome (EPS)</arm_group_label>
    <other_name>Puyanhewei capsule administration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consecutive outpatients aged 18 to 75 years old.

          2. FD patients defined by the Rome III classification.

          3. Willing to choose pCLE and no organic diseases.

        Exclusion Criteria:

          1. Severe liver, heart, or kidney diseases.

          2. Current or past evidence of uncontrolled diabetes mellitus, psychosomatic disorders,
             such as depressive and anxiety disorders, and drug or alcohol abuse.

          3. Pregnant or breastfeeding women.

          4. Inability to give informed consent.

          5. Use of nonsteroidal anti-inflammatory drugs, proton pump inhibitors, H2-receptor
             antagonists, antacids, prokinetics, or other injurious drugs (antibiotics, and
             steroids) in the prior two weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanqing Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital, Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanqing Li, MD.PhD.</last_name>
    <phone>86-531-82169236</phone>
    <phone_ext>82169508</phone_ext>
    <email>liyanqing@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology, Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqing Li, MD.PhD.</last_name>
      <phone>86-531-82169236</phone>
      <phone_ext>82169508</phone_ext>
      <email>liyanqing@sdu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yanqing Li, MD. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui Ji, MD. PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kang Jiang, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiu-Li Zuo, MD. PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Yanqing Li</investigator_full_name>
    <investigator_title>Vice president of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>barrier dysfunction</keyword>
  <keyword>functional dyspepsia</keyword>
  <keyword>Confocal Laser Endomicroscopic</keyword>
  <keyword>therapeutic response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

